Breaking News Instant updates and real-time market news.

ARNA

Arena Pharmaceuticals

$24.29

0.22 (0.91%)

, VLRX

Valeritas

$3.50

0.24 (7.36%)

04:55
09/15/17
09/15
04:55
09/15/17
04:55

European Association for the Study of Diabetes to hold annual meeting

53rd Annual Meeting of EASD 2017 is being held in Lisbon, Portugal on September 11-15.

ARNA

Arena Pharmaceuticals

$24.29

0.22 (0.91%)

VLRX

Valeritas

$3.50

0.24 (7.36%)

VTVT

vTv Therapeutics

$5.37

-0.05 (-0.92%)

  • 15

    Sep

  • 25

    Sep

  • 26

    Sep

ARNA Arena Pharmaceuticals
$24.29

0.22 (0.91%)

06/27/17
06/27/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. JPMorgan analyst Alex Yao resumed coverage of Alibaba (BABA) Group with an Overweight rating and $190 price target following a period of restriction. The rating is unchanged and the price target is raised from $140. 2. SunTrust analyst Terry Tillman initiated Salesforce (CRM) with a Buy and a $110 price target and views its as a core holding for large-cap investors. 3. Citi analyst Joel Beatty started Arena Pharmaceuticals (ARNA) with a Buy rating and $23 price target. 4. Deutsche Bank analyst Bryan Kraft started Lionsgate Class A (LGF.A) shares with a Hold rating and $29 price target. 5. Cantor Fitzgerald analyst Louise Chen assumed coverage of Amarin (AMRN) with an Overweight rating and $10 price target. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/11/17
LEER
07/11/17
NO CHANGE
Target $53
LEER
Outperform
Arena Pharmaceuticals price target raised to $53 from $47 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Arena Pharmaceuticals to $53 from $47 after the company reported "promising" topline results from its Phase 2 ralinepag study in pulmonary arterial hypertension that surpassed the benchmark established by its competitor selexipag. On the heels of ralinepag data, the analyst believes investors will begin to assign greater value to the company's proprietary pipeline that could present further upside in not only mass-market indications like ulcerative colitis and pain, but also in the rare manifestations including pyoderma gangrenosum and extraintestinal manifestations. Schwartz reiterates an Outperform rating on the shares.
07/11/17
JMPS
07/11/17
NO CHANGE
JMPS
Arena Pharmaceuticals price target raised to $36 from $27 at JMP Securities
JMP Securities analyst Jason Butler says that the Phase 2 results of Arena's Ralinepag in PAH indicates that it has "a compelling clinical profile" that supports "a blockbuster commercial opportunity." The analyst adds that the drug can become "the best-in-class oral prostacyclin receptor agonist." He raised his price target on the shares to $36 from $27 and keeps an Outperform rating on the stock.
07/11/17
SBSH
07/11/17
NO CHANGE
Target $37
SBSH
Buy
Arena Pharmaceuticals price target raised to $37 from $23 at Citi
VLRX Valeritas
$3.50

0.24 (7.36%)

07/10/17
WEDB
07/10/17
INITIATION
Target $12
WEDB
Outperform
Valeritas initiated with an Outperform at Wedbush
Pre-open, Wedbush analyst Tao Levy initiated Valeritas with an Outperform and a $12 price target telling investors the company is well positioned to increase adoption of its V-Go platform, a wearable insulin delivery device, after recently raising additional capital and completing a significant adjustment in its commercialization strategy.
04/17/17
COWN
04/17/17
INITIATION
COWN
Outperform
Valeritas initiated with an Outperform at Cowen
Cowen analyst Doug Schenkel initiated Valeritas with an Outperform saying its revamped commercial strategy under a different management structure has yielded promising early results. The analyst believes Valeritas has a differentiated insulin pump specifically for Type 2 patients within a $2-3B+ US TAM, and at a $100MM enterprise value, there could be material upside if management executes relative to expectations in 2017 and beyond.
09/27/16
RILY
09/27/16
INITIATION
Target $7.5
RILY
Buy
Valeritas initiated with a Buy at B. Riley
B. Riley analyst Greg Chodaczek started Valeritas with a Buy rating and $7.50 price target.
VTVT vTv Therapeutics
$5.37

-0.05 (-0.92%)

09/26/16
HCWC
09/26/16
INITIATION
Target $13
HCWC
Buy
vTv Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started vTv Therapeutics with a Buy rating and $13 price target.
12/15/16
HCWC
12/15/16
NO CHANGE
Target $13
HCWC
Buy
vTv Therapeutics Phase 2 diabetes data a 'big win,' says H.C. Wainwright
H.C. Wainwright analyst Corey Davis views vTv Therapeutics' (VTVT) data from its Phase 2 study of TTP273 in type-2 diabetes as "very positive" and a "big win." Efficacy is close to Novo Nordisk's (NVO) oral semaglutide, Davis tells investors in a research note. vTv is "highly likely" to succeed in finding a partner given the attractiveness of the diabetes market and the differentiated profile '273 has now created, the analyst contends. Davis keeps a Buy rating on the shares with a $13 price target.
12/15/16
STFL
12/15/16
NO CHANGE
STFL
vTv Therapeutics price target raised to $14 from $12 at Stifel
Stifel analyst Thomas Shrader believes that vTv's TTP273 showed positive results in a Phase IIb trial of T2d patients. The analyst thinks that the drug " has demonstrated proof of concept with hints of an improved safety profile relative to Byetta." He predicts that vTv will obtain a partner for the drug and will receive " a $100M - $200M upfront payment and low double digit royalties on sales." Shrader keeps a Buy rating on the shares.
03/29/17
STFL
03/29/17
NO CHANGE
Target $14
STFL
Buy
vTv Therapeutics TTP399 safety data looked 'very promising,' says Stifel
Stifel analyst Thomas Shrader said the safety data from vTv Therapeutics' Phase 2 trial of TTP399 looked "very promising" and appear to him to be "strong enough" to drive a partnership, which is likely required for the next stages of the drug's development. Shrader keeps a Buy rating and $14 price target on vTv shares.

TODAY'S FREE FLY STORIES

IOVA

Iovance Biotherapeutics

$7.15

-1.4 (-16.37%)

19:46
09/20/17
09/20
19:46
09/20/17
19:46
Syndicate
Iovance Biotherapeutics 7.69M share Secondary priced at $6.50 »

The deal priced at $6.50,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 21

    Sep

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

, CAB

Cabela's

$61.45

0.07 (0.11%)

18:28
09/20/17
09/20
18:28
09/20/17
18:28
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P SmallCap 600…

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

CAB

Cabela's

$61.45

0.07 (0.11%)

TPRE

Third Point Reinsurance

$14.40

-0.1 (-0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WDC

Western Digital

$86.37

-3.55 (-3.95%)

, TOSYY

Toshiba, also use TOSBF

$17.08

-0.29 (-1.67%)

18:26
09/20/17
09/20
18:26
09/20/17
18:26
Hot Stocks
Sandisk subsidiaries initiate new arbitration proceedings against Toshiba »

Western Digital (WDC)…

WDC

Western Digital

$86.37

-3.55 (-3.95%)

TOSYY

Toshiba, also use TOSBF

$17.08

-0.29 (-1.67%)

TOSBF

Toshiba, also use TOSYY

$2.87

-0.02 (-0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOA

North American Energy

$4.10

-0.05 (-1.20%)

18:26
09/20/17
09/20
18:26
09/20/17
18:26
Hot Stocks
North American Energy awarded two earthworks contracts for $90M »

North American Energy has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ISTR

Investar Holding

$23.15

0.15 (0.65%)

18:01
09/20/17
09/20
18:01
09/20/17
18:01
Hot Stocks
Investar Holding raises quarterly dividend to 3c from 2c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$47.86

-0.63 (-1.30%)

17:56
09/20/17
09/20
17:56
09/20/17
17:56
Syndicate
Beacon Roofing 6.325M share Secondary priced at $47.50 »

BofA/Merrill, RBC Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

AMD

AMD

$13.74

0.62 (4.73%)

, AMPH

Amphastar

$15.64

-0.02 (-0.13%)

17:46
09/20/17
09/20
17:46
09/20/17
17:46
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: AMD (AMD), up 6%…

AMD

AMD

$13.74

0.62 (4.73%)

AMPH

Amphastar

$15.64

-0.02 (-0.13%)

GVP

GSE Systems

$2.80

0.05 (1.82%)

MLHR

Herman Miller

DPS

Dr Pepper Snapple

$91.68

-0.12 (-0.13%)

JUNO

Juno Therapeutics

$45.21

1.41 (3.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 28

    Sep

ABMD

Abiomed

$157.42

0.32 (0.20%)

17:36
09/20/17
09/20
17:36
09/20/17
17:36
Hot Stocks
Abiomed receives FDA PMA approval for Impella RP for right heart failure »

Abiomed has received FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSK

Oshkosh

$79.69

0.34 (0.43%)

17:35
09/20/17
09/20
17:35
09/20/17
17:35
Hot Stocks
Oshkosh awarded $466.7M government contract modification »

Oshkosh Defense, Oshkosh,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AET

Aetna

$155.03

-1.01 (-0.65%)

17:32
09/20/17
09/20
17:32
09/20/17
17:32
Hot Stocks
Aetna president Lynch sells $2.5M of company shares »

The president of health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APRN

Blue Apron

$5.22

-0.29 (-5.26%)

17:25
09/20/17
09/20
17:25
09/20/17
17:25
Hot Stocks
Blue Apron jumps after meal kit competitor Plated acquired by Albertsons »

Earlier today, food…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPS

Dr Pepper Snapple

$91.68

-0.12 (-0.13%)

17:22
09/20/17
09/20
17:22
09/20/17
17:22
Earnings
Dr Pepper Snapple cuts FY17 EPS view to $4.53-$4.63 from $4.56-$4.66 »

FY17 consensus $4.63. In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBI

Hanesbrands

$24.64

-0.07 (-0.28%)

17:22
09/20/17
09/20
17:22
09/20/17
17:22
Downgrade
Hanesbrands rating change at Nomura Instinet »

Hanesbrands downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPRE

Third Point Reinsurance

$14.40

-0.1 (-0.69%)

, SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

17:19
09/20/17
09/20
17:19
09/20/17
17:19
Hot Stocks
Breaking Hot Stocks news story on Third Point Reinsurance, Sanderson Farms »

Third Point Reinsurance…

TPRE

Third Point Reinsurance

$14.40

-0.1 (-0.69%)

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

, CAB

Cabela's

$61.45

0.07 (0.11%)

17:18
09/20/17
09/20
17:18
09/20/17
17:18
Hot Stocks
Sanderson Farms to replace Cabela's in S&P 400 at open on 9/26 »

Bass Pro Shops is…

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

CAB

Cabela's

$61.45

0.07 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPCI

Intellipharmaceutics

17:14
09/20/17
09/20
17:14
09/20/17
17:14
Hot Stocks
Intellipharmaceutics receives Nasdaq non-compliance notice »

Intellipharmaceutics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

RWLK

ReWalk Robotics

17:13
09/20/17
09/20
17:13
09/20/17
17:13
Syndicate
Breaking Syndicate news story on ReWalk Robotics »

ReWalk Robotics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABM

ABM

$39.29

0.23 (0.59%)

17:11
09/20/17
09/20
17:11
09/20/17
17:11
Hot Stocks
Breaking Hot Stocks news story on ABM »

Thomas H. Lee Advisors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IVTY

Invuity

$8.35

-0.15 (-1.76%)

17:07
09/20/17
09/20
17:07
09/20/17
17:07
Hot Stocks
Breaking Hot Stocks news story on Invuity »

Discovery Group raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 16

    Nov

USG

USG

$31.26

1.84 (6.25%)

, CBPX

Continental Building

$25.60

1.25 (5.13%)

17:04
09/20/17
09/20
17:04
09/20/17
17:04
Hot Stocks
Gypsum stocks jump after peer National Gypsum announces price increase »

Shares of companies…

USG

USG

$31.26

1.84 (6.25%)

CBPX

Continental Building

$25.60

1.25 (5.13%)

EXP

Eagle Materials

$105.07

2.9 (2.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

TRHC

Tabula Rasa HealthCare

$25.66

-0.38 (-1.46%)

16:46
09/20/17
09/20
16:46
09/20/17
16:46
Recommendations
Tabula Rasa HealthCare analyst commentary at Piper Jaffray »

Tabula Rasa HealthCare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

16:40
09/20/17
09/20
16:40
09/20/17
16:40
General news
Fed Leans into Wind on Balance Sheet: »

Fed Leans into Wind on…

TPIV

TapImmune

$3.08

-0.01 (-0.32%)

16:37
09/20/17
09/20
16:37
09/20/17
16:37
Syndicate
Breaking Syndicate news story on TapImmune »

TapImmune files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBSB

Meridian Bancorp

$18.15

0.1 (0.55%)

16:36
09/20/17
09/20
16:36
09/20/17
16:36
Hot Stocks
Meetinghouse receives shareholder approval for merger with Meridian Bancorp »

Meridian Bancorp, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRNY

Kearny Financial

$15.10

0.2 (1.34%)

16:34
09/20/17
09/20
16:34
09/20/17
16:34
Hot Stocks
Kearny Financial declares special cash dividend of 12c per share »

Kearny Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.